Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study Academic Article uri icon

Overview

MeSH Major

  • Antiviral Agents
  • Hepatitis C, Chronic
  • Postoperative Complications
  • Registries

abstract

  • In a large prospective observational cohort study, direct-acting antiviral therapy with SOF/ledipasvir, ombitasvir/paritaprevir/ritonavir + dasabuvir, and SOF plus daclatasvir was efficacious and safe in LT, KT, and DLK transplant recipients; ribavirin did not influence SVR, and graft rejection was rare. (Hepatology 2017;66:1090-1101).

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/hep.29258

PubMed ID

  • 28504842

Additional Document Info

start page

  • 1090

end page

  • 1101